Menu

Focus On

Home>Focus On>Page 5
210406_Focus-On_ITACTA-On-Demand_653x337px
Events

ITACTA WEBINAR – ON-DEMAND

The webinar entitled “Endotoxemia and role of Polymyxin B hemoperfusion in the cardiovascular intensive care unit” held in collaboration with ITACTA (Italian Association of Cardiothoracic Anaesthesiologists)is now available ON-DEMAND. This webinar aims to describe and discuss the pathogenic action of endotoxemia in various clinical contests of patients hospitalized in a cardiovascular intensive care unit and the role of Polymyxin B hemoperfusion as possible therapeutic option in adult and pediatric patients.

210406_Focus-On_ITACTA_653x337px
Events

ITACTA WEBINAR

On April 15th, 2021, at 5pm (CEST), in collaboration with ITACTA (Italian Association of Cardiothoracic Anaesthesiologists) Estor is supporting an Italian language webinar entitled: “Endotoxemia and role of Polymyxin B hemoperfusion in the cardiovascular intensive care unit”.
This webinar aims to describe and discuss the pathogenic action of endotoxemia in various clinical contests of patients hospitalized in a cardiovascular intensive care unit and the role of Polymyxin B hemoperfusion as possible therapeutic option in adult and pediatric patients.

210401_Focus-On_Hemofeel_653x337px
Clinical research

Reduction of complement activation and renal dysfunction with PMMA-based CVVH treatment in sepsis-induced AKI

New relevant findings on the role of polymethylmethacrylate (PMMA)-based CVVH in an animal model of sepsis-induced AKI have been published in Frontiers in Immunology. The results show that PMMA-based CVVH significantly reduces tissue and systemic complement activation limiting renal damage and fibrosis highlighting the potential role of PMMA membrane as a therapeutic strategy in patients with septic acute kidney injury (AKI).

210521_Focus-On_Toraymyxin-PMX05R_653x337px
Therapy

A “small” big revolution in blood purification therapies for sepsis: TORAYMYXIN® PMX-05R

We are proud to launch Toraymyxin® PMX-05R, Polymyxin B hemoperfusion therapy medical device specifically designed for the management of un-responsive septic shock in patients with reduced body volume. The reduced size PMX-05R device is the ideal choice for smaller body volume patients guaranteeing the unique properties and performances of Polymyxin B hemoperfusion, maintaining the high quality standards of TORAY and fully responding to global clinical needs.

210212_Focus-On_Fujimori_635x337px
Clinical research

Survival Benefit of Polymyxin B Hemoperfusion in Septic Shock Patients Requiring Noradrenaline

Results from the Nationwide Administrative Database in Japan concerning adults diagnosed with septic shock and requiring noradrenaline support during the period 2016-2019 have been published in the Blood Purification journal by Fujimori and co-workers.

210112-PMX_COVID-19_EUPHAS2-653x337px
Clinical research

COVID-19 and Polymyxin B Hemoperfusion – Data from the EUPHAS-2 registry

Polymyxin B hemoperfusion experience from critically ill COVID-19 patients with endotoxic shock has been published recently in Artificial Organs. The study refers to 12 COVID-19 patients hospitalized in ICU who developed a secondary infection – endotexemia leading to septic shock status and whose data were collected in the observational study EUPHAS 2 from February to May 2020, showing very interesting results.

201118-ESICM-LIVES-2020-653x337px
Events

ESICM LIVES 2020

ESICM LIVES 2020 is approaching and will be held virtually on December 6-9, 2020. Estor is partner of ESICM LIVES supporting the symposium entitled “Endotoxic shock and role of advanced blood purification therapies on December 8 at 12.30-13.30 on Channel Milan.

201126-PMX_COVID-19-653x337px
Clinical research

Critically ill COVID-19 patients and the role of Polymyxin B hemoperfusion

Over the last year, various works in literature have revealed the potential role of Polymyxin B Hemoperfusion in the management of non-responsive COVID-19 patients admitted to intensive care. We report here various case reports that have been presented as abstracts at international congresses and/or published in peer-reviewed journals on the use of Polymyxin B hemoperfusion in COVID-19 patients.

201106-Vicenza-Course-2020-HIGHLIGHTS-653x337px
Events

Highlights from Vicenza Course 2020

Interesting findings and new data on endotoxemia, endotoxic shock, implications in COVID-19 disease, role of Polymyxin B hemoperfusion and new approaches in septic AKI, were presented during the 38th International Vicenza Course on AKI and CRRT organized by Prof. Ronco which took place virtually from November 2-6 , 2020.